Publications by authors named "Rabab Gaafar"

Claim this Profile
P
Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus.
Hussein Khaled, Yousry Wasef Nada, Kareem Mohamed Ramadan, Shawkat Fekry, Mohamed Samy Seleam, Rabab Gaafar

J Egypt Natl Canc Inst· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.
Ibrahim Malash, Osman Mansour, Rabab Gaafar, Sabry Shaarawy, Mona S Abdellateif

J Egypt Natl Canc Inst· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa.
Abdul Rahman Jazieh, Rabab Gaafar, Hassan Errihani, Hassan Jaafar, Fouad Al Dayel

JCO Glob Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
Catherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, Rabab Gaafar, Henda Rais

Breast Cancer Res Treat· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer in the Middle East and North Africa Region.
Abdulrahman R Jazieh, Ghada Algwaiz, Hassan Errihani, Ibrahim Elghissassi, Layth Mula-Hussain, Rabab Gaafar

J Thorac Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib in locally advanced/metastatic NSCLC harboring common mutations, after chemotherapy: a Phase IV study.
Sumitra Thongprasert, Sarayut L Geater, Dana Clement, Amr Abdelaziz, Jasmin Reyes-Igama, Rabab Gaafar

Lung Cancer Manag· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF Mutation-Positive Metastatic Malignancy.
Weijiang Zhang, Christine McIntyre, Harper Forbes, Rabab Gaafar, Hanaa Kohail

Clin Pharmacol Drug Dev· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.
Catherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, Rabab Gaafar, Henda Rais

Breast Cancer Res Treat· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Giorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, Takashi Nakano, Jan van Meerbeeck

Lancet Respir Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Vanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, Francesco Grossi, Jacek Jassem

Lancet Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
Marwa Mahmoud Hussein, Rabab Mohamed Gaafar, Ahmed Mostafa Abdel-Warith, Wafaa Abdallah Ahmed, Nasr Mohamed Ali Allahloubi

Clin Breast Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contributing factors to the outcome of primary malignant chest wall tumors.
Abdel Rahman Mohamed Abdel Rahman, Mohamed Rahouma, Rabab Gaafar, Sherif Bahaa, Iman Loay

J Thorac Dis· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Giorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, Martin Reck, Anne S Tsao

Clin Lung Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
Katsuyuki Hotta, Yuka Kato, Natasha Leighl, Nagio Takigawa, Rabab Mohamed Gaafar

PLoS One· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
Mary E R O'Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer

Eur J Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists.
Nicholas Pavlidis, Hussein Khaled, Rabab Gaafar

J Adv Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
Lee M Krug, Hedy L Kindler, Hilary Calvert, Christian Manegold, Anne S Tsao, Rabab M Gaafar

Lancet Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
Baktiar Hasan, Laurent Greillier, Athanasios Pallis, Jessica Menis, Rabab Gaafar

Eur J Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer.
Ahmed Abdallah, Mohamed Belal, Ahmed El Bastawisy, Rabab Gaafar

Oncol Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin.
Rabab Gaafar, Abdel Rahman M Abdel Rahman, Fatma Aboulkasem, Ahmed El Bastawisy

Ecancermedicalscience· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, Francesco Grossi, Allan Price

Eur J Cancer· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
Jaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, Mary E R O'Brien, Baktiar Hasan, Rabab Gaafar

Eur J Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.
Nabil Mubarak, Rabab Gaafar, Samir Shehata, Tarek Hashem, Dani Abigeres

BMC Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
Abeer A Bahnassy, Abdel-Rahman N Zekri, Amany A Abou-Bakr, Mervat M El-Deftar, Ahmad El-Bastawisy, Rabab M Gaafar

Exp Mol Pathol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer.
Amal Fawzy, Rabab Gaafar, Fatma Kasem, Shawkey S Ali, Mostafa Elshafei

J Egypt Natl Canc Inst· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis